Psych MEQs / SAQs · Consultation-liaison psychiatry
Delirium diagnosis, work-up, and management (MEQ)
FRANZCP-style MEQ on delirium: CAM/hypoactive miss, causes, non-drug first care, limited antipsychotics with trial evidence, and capacity.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Diagnosis and CAM. Working diagnosis: delirium superimposed on dementia (DSD), currently hypoactive (quiet, delayed responses) after overnight hyperactive features — likely mixed motor course over 24 hours. CAM reasoning: acute change from baseline with fluctuation (overnight agitation to morning quiet); inattention (fails months backward); plus altered level of consciousness (drowsy/slow). Visual or behavioural disturbance overnight supports the syndrome. This is not primary psychosis and is not "just dementia progression."[1][2]
(ii) Precipitants, work-up, non-drug plan. Precipitants: infection (pneumonia), anticholinergic (oxybutynin), benzodiazepine (temazepam), opioid (oxycodone), hospital environment/sleep disruption, possible hypoxia, dehydration, constipation/retention. Immediate plan: ABCDE and oxygen/glucose; cultures/CXR as indicated; bloods (FBC, U&E, Ca/Mg, CRP, LFTs); bladder scan; medication review — stop or minimise oxybutynin/temazepam/oxycodone where possible; sensory aids; reorientation; family presence; day-night cues; early mobilisation; hydration; avoid restraint. Multicomponent non-pharmacological care is first-line prevention and treatment infrastructure.[2][5][6]
(iii) Antipsychotics. Do not treat the syndrome itself with antipsychotics. Evidence: MIND-USA — no benefit of haloperidol/ziprasidone vs placebo for ICU days without delirium/coma; Agar — risperidone/haloperidol worse than placebo for palliative delirium symptoms; systematic reviews do not support routine use. Reserve low-dose short-term agent only if severe distress or imminent danger persists after non-drug measures and medical optimisation — e.g. haloperidol 0.25–0.5 mg PO/IM with ECG/QTc and EPS monitoring, or quetiapine 12.5–25 mg, or olanzapine 2.5–5 mg, daily review, stop early. Not "something strong for psychosis."[3][4][6]
(iv) Capacity and disposition. Capacity is decision-specific. A cheerful "yes" to going home does not prove understanding, retention, or weighing of pneumonia treatment risks. Document impairment, treat delirium, reassess in a lucid window if possible, use least-restrictive local legal frameworks and substitute decision-makers as required. Do not process unsafe self-discharge while CAM-positive without a safety plan.[2][6]
Common errors
Common scoring traps: calling this primary schizophrenia or pure dementia progression; high-dose IM antipsychotic as first step; benzodiazepines for non-withdrawal delirium; ignoring anticholinergic and opioid contributions; and treating a single "yes" as full capacity for discharge.[2][3][6]
Examiner notes
Reward explicit CAM features, hypoactive miss, named deliriogenic drugs, multicomponent care, trial-honest antipsychotic limits, and capacity functional analysis.[1][3][5]
References
- [1]Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion: the confusion assessment method. A new method for detection of delirium Ann Intern Med, 1990.PMID 2240918
- [2]Marcantonio ER Delirium in Hospitalized Older Adults N Engl J Med, 2017.PMID 29020579
- [3]Girard TD, Exline MC, Carson SS, et al. Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness N Engl J Med, 2018.PMID 30346242
- [4]Agar MR, Lawlor PG, Quinn S, et al. Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial JAMA Intern Med, 2017.PMID 27918778
- [5]Inouye SK, Bogardus ST Jr, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients N Engl J Med, 1999.PMID 10053175
- [6]Oh ES, Fong TG, Hshieh TT, et al. Delirium in Older Persons: Advances in Diagnosis and Treatment JAMA, 2017.PMID 28973626